Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $7.00 → $10.00 | Underweight → Neutral | JP Morgan |
| 1/3/2023 | $32.00 → $31.00 | Buy | Needham |
| 11/4/2021 | $20.00 → $19.00 | Neutral → Underweight | JP Morgan |
| 11/4/2021 | $78.00 → $71.00 | Buy | HC Wainwright & Co. |
| 11/4/2021 | $41.00 → $24.00 | Outperform | Raymond James |
| 10/15/2021 | $51.00 | Buy | BTIG Research |
| 9/30/2021 | $24.00 → $20.00 | Overweight → Neutral | JP Morgan |
| 9/1/2021 | $57.00 → $56.00 | Buy | Roth Capital |
15-12G - G1 Therapeutics, Inc. (0001560241) (Filer)
S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)
S-8 POS - G1 Therapeutics, Inc. (0001560241) (Filer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer death
- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced that Pharmacosmos A/S has successfully completed the previously announce
HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to Pharmacosmos' previously announced acquisition of G1 Therapeutics. The expiration of the waiting period occurred at 11:59 p.m. EST on September 4, 2
JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously
Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously
JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi